Ana Garrido

Barcelona, CT 08916, Spain

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 43 publications

Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model.

Precision targeting of CXCR4+ leukemia cells by a humanized MMAE-nanoconjugate in an AML mouse model.

Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

Published: July 15, 2025

A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study.

A scoring system to predict life-threatening thromboischemic events in patients with acute promyelocytic leukemia: the PETHEMA/PALG study.

Journal: Haematologica

Published: June 26, 2025

Standard Versus Reduced-Doses of Post-Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell Transplantation.

Standard Versus Reduced-Doses of Post-Transplant Cyclophosphamide in HLA Matched (10/10) Peripheral Blood Stem Cell Transplantation.

Journal: European journal of haematology

Published: June 10, 2025

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Prognostic value of measurable residual disease (MRD) for venetoclax in combination with hypomethylating agents in patients diagnosed with acute myeloid leukemia: validation of the ELN-2021 MRD recommendations.

Journal: Blood cancer journal

Published: February 11, 2025

Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.

Measurable Residual Disease in UBTF-TD Adult Acute Myeloid Leukemia.

Journal: European journal of haematology

Published: November 20, 2024

Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.

Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.

Journal: Cancers

Published: October 27, 2024

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.

Journal: Blood cancer journal

Published: October 17, 2024

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia.

Real-life outcome after failure to venetoclax and hypomethylating-based therapy for acute myeloid leukemia.

Journal: Haematologica

Published: September 07, 2024

Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation.

Severity and organ distribution of graft-versus-host disease with post-transplant cyclophosphamide versus calcineurin inhibitor plus methotrexate/mycophenolate mofetil or sirolimus in allogenic HLA-matched or single-allele mismatched stem cell transplantation.

Journal: European journal of haematology

Published: June 28, 2024

Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.

Incidence, risk factors, and outcomes of second neoplasms in patients with acute promyelocytic leukemia: the PETHEMA-PALG experience.

Journal: Annals of hematology

Published: July 29, 2023

Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience.

Outcome improvement over time in reduced intensity conditioning hematopoietic transplantation: a 20-year experience.

Journal: Annals of hematology

Published: May 26, 2023

Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.

Successful Outcome in Patients with Myelofibrosis Undergoing Allogeneic Donor Hematopoietic Cell Transplantation Using Reduced Doses of Post-Transplantation Cyclophosphamide: Challenges and Review of the Literature.

Journal: Transplantation and cellular therapy

Published: February 27, 2023

Showing 1-12 of 43

Last Updated: 09/26/2026